(Q71181710)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

title

Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference

R E Kessler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

J Fung-Tomc

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

publication date

1 June 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

16 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

issue

6A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

page(s)

13S-19S

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin

16 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

In vitro activity of carumonam (RO 17-2301), BMY-28142, aztreonam, and ceftazidime against 7,620 consecutive clinical bacterial isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

In-vitro activity of BMY 28142, a new aminothiazolyl cephalosporin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

In vitro activity of BRL 36650, a new penicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Cefepime: overview of activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Antibacterial activity of cefepime in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

In-vitro activity of cefepime and other antimicrobials: survey of European isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Sensitivity of Escherichia coli to various beta-lactams is determined by the interplay of outer membrane permeability and degradation by periplasmic beta-lactamases: a quantitative predictive treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

Antimicrobial activity of new antibiotics against bacterial isolates from a community hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900103-9

10.1016/S0002-9343(96)00103-9

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8678092%20AND%20SRC:MED&resulttype=core&format=json

16 October 2019

1 reference